-

Viz.ai Names Michael Herring as Chief Financial Officer

Seasoned financial leader brings experience at leading companies in healthcare and software as a service (SaaS) to help company scale and drive durable growth

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has named financial leader Michael Herring as chief financial officer (CFO). Mr. Herring will report to CEO Chris Mansi, leading financial strategies and overseeing the global financial organization, including planning, treasury, tax, reporting and investor relations.

“Michael’s deep experience in guiding both public and private companies will be invaluable as Viz.ai continues to scale,” said Chris Mansi, MD, CEO and co-founder at Viz.ai. “He brings a proven track record of driving strong and sustainable financial growth and deepens our leadership bench to accelerate our impact on more patients.”

Mr. Herring is a seasoned financial executive with more than 30 years of experience. He most recently served as CFO at Color Health, a health technology company, where he led the financial infrastructure and operations teams to support the company’s growth and deliver critical medical care to millions during the COVID-19 pandemic. Previously, he served as business finance officer (BFO) at Google for the Android, Play and Chrome product lines, president and CFO at Pandora Media, global operations lead at Adobe, and CFO at Omniture and Ancestry.com where he helped establish business models that scaled to over $1B in revenue.

“Now, more than ever, we need AI-powered care that increases access to life-saving treatments across our hospitals and healthcare systems,” said Mr. Herring. “I look forward to playing a meaningful role in the next chapter of Viz.ai’s growth and delivering on our mission to make healthcare work faster and smarter.”

Herring earned a bachelor’s degree in Economics from the University of California at Los Angeles and is a Certified Public Accountant.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,500+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai OneTM is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Contacts

Viz.ai


Release Versions

Contacts

Social Media Profiles
More News From Viz.ai

Viz.ai and NCCN Collaborate to Integrate NCCN Guidelines into Clinical Workflows for Oncologists

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced an agreement with the National Comprehensive Cancer Network® (NCCN®). This collaboration integrates NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast, Prostate, and Bladder Cancer into the Viz Oncology Platform making this important information readily available to clinicians when they’re making critical decisions about patient care. Thr...

Viz.ai Appoints Dr. Timothy N. Showalter as First Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the appointment of Tim Showalter, MD, MPH, MBA, as its first Chief Medical Officer (CMO). Dr. Showalter, an accomplished academic radiation oncologist, will lead Viz.ai’s clinical strategy and advance the company’s mission to use artificial intelligence to improve access to life-saving care. He will report to Chris Mansi, MD, CEO and co-founder of Viz.ai. Dr. Sho...

New Data Show Viz.ai’s AI-Enabled ECG Screening Increases Detection and Accelerates Diagnosis of Hypertrophic Cardiomyopathy

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data demonstrating how Viz HCM enables faster, accurate detection of hypertrophic cardiomyopathy (HCM), to help ensure that more patients are identified. Two studies, which will be presented at the American Heart Association (AHA) Scientific Sessions 2025, show Viz.ai’s real-world ability to identify more patients with HCM years earlier than current...
Back to Newsroom